Biocept Sets Price Range on Proposed IPO; Anticipates $17.7M in Net Proceeds | GenomeWeb

NEW YORK (GenomeWeb News) – Biocept today set the price range on its planned initial public offering, saying it expects to price its shares between $10 and $12.

In its amended Form S-1 filed on Tuesday with the US Securities and Exchange Commission, the circulating tumor cell diagnostics firm said that it expects to offer about 1.8 million shares of its common stock, netting proceeds of approximately $17.1 million at the midpoint price of $11 per share. It would net $20.5 million if the underwriters exercise their overallotment option in full.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.